SCYNEXIS Inc SCYX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:52 PM EDT
1.87quote price arrow up+0.01 (+0.62%)
Volume
30,808
52 week range
1.70 - 8.10
Loading...
  • Open1.89
  • Day High1.90
  • Day Low1.86
  • Prev Close1.86
  • 52 Week High8.10
  • 52 Week High Date11/26/21
  • 52 Week Low1.70
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap60.97M
  • Shares Out32.58M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta2.01
  • YTD % Change-69.32

KEY STATS

  • Open1.89
  • Day High1.90
  • Day Low1.86
  • Prev Close1.86
  • 52 Week High8.10
  • 52 Week High Date11/26/21
  • 52 Week Low1.70
  • 52 Week Low Date06/14/22
  • Market Cap60.97M
  • Shares Out32.58M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta2.01
  • YTD % Change-69.32

RATIOS/PROFITABILITY

  • EPS (TTM)-1.21
  • P/E (TTM)-1.55
  • Fwd P/E (NTM)-0.90
  • EBITDA (TTM)-78.456M
  • ROE (TTM)-103.75%
  • Revenue (TTM)1.80M
  • Gross Margin (TTM)77.17%
  • Net Margin (TTM)-1,868.94%
  • Debt To Equity (MRQ)114.39%

EVENTS

  • Earnings Date08/15/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On SCYNEXIS Inc

There is no recent news for this security.

Profile

MORE
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. It has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast...
Guy Macdonald
Non-Executive Independent Chairman of the Board
Marco Taglietti M.D.
President, Chief Executive Officer, Director
Lawrence Hoffman CPA., Esq.
Interim Chief Financial Officer
Scott Sukenick J.D.
General Counsel
Nkechi Azie M.D.
Vice President - Clinical Development
Address
3501-C TRICENTER BLVD
Durham, NC
27713
United States

Top Peers

SYMBOLLASTCHG%CHG
INFI
Infinity Pharmaceuticals Inc
0.60-0.0323-5.1083%
ZYNE
Zynerba Pharmaceuticals Inc
1.15+0.01+0.44%
TRVN
Trevena Inc
0.3854-0.0286-6.9082%
AVTX
Avalo Therapeutics Inc
0.5213+0.0213+4.26%
SEEL
Seelos Therapeutics Inc
0.658-0.0223-3.278%